n-myristoylglycine profile

N-myristoylglycine (MyrGly) is a fatty acid amide that is a component of the myristoylated protein N-myristoyltransferase (NMT) enzyme, which catalyzes the attachment of myristate to proteins. MyrGly is a potent inhibitor of NMT and has been shown to have anti-inflammatory and anti-cancer effects. The compound is also a substrate for the enzyme fatty acid amide hydrolase (FAAH), which is responsible for the breakdown of fatty acid amides. MyrGly has been studied for its potential therapeutic applications in the treatment of inflammatory diseases, cancer, and other conditions. It is synthesized by the reaction of myristoyl chloride with glycine in the presence of a base. The synthesis and biological activity of MyrGly have been investigated in several studies, and it has been shown to be a promising drug candidate for various diseases.'

N-myristoylglycine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-myristoylglycine : An N-acylglycine in which the acyl group is specified as myristoyl (tetradecanoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	72348
CHEMBL ID	4854669
CHEBI ID	87142
SCHEMBL ID	343546
MeSH ID	M0160630

Synonym
nsc-622050
nsc622050
n-myristoylglycine
2-(tetradecanoylamino)acetic acid
14246-55-0
n-tetradecanoylglycine
glycine,n-(1-oxotetradecyl)-
84uk82t430 ,
unii-84uk82t430
glycine, n-(1-oxotetradecyl)-
n-myristoyl-gly
FT-0637042
SCHEMBL343546
myristoyl-gly-oh
tetradecanoylglycine
CHEBI:87142
myristoylglycine
DTXSID10162047
n-(1-oxotetradecyl)glycine
n-myristoyl glycine
2-tetradecanamidoacetic acid
myristoyl-gly-oh, aldrichcpr
mfcd00155627
n-myristoyl-glycine
AKOS027328012
n-myristoylglycine, analytical reference material
myristoyl glycine
J-007658
acylglycine c:14
Q27159399
CS-0111612
FD21630
?myristoyl glycine
CHEMBL4854669
mryistoyl-gly-oh

Role	Description
human urinary metabolite	Any metabolite (endogenous or exogenous) found in human urine samples.
human blood serum metabolite	Any metabolite (endogenous or exogenous) found in human blood serum samples.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
N-acylglycine	An N-acyl-amino acid in which amino acid specified is glycine.
fatty amide	A monocarboxylic acid amide derived from a fatty acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Assay ID	Title	Year	Journal	Article
AID1751482	Antibacterial activity in Staphylococcus aureus assessed as bacterial growth rate at 100 uM measured by UV absorbance based analysis	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Discovery of non-proteinogenic amino acids inhibiting biofilm formation by S. aureus and methicillin-resistant S. aureus.
AID1751483	Antibiofilm activity against Staphylococcus aureus assessed as biofilm formation at 100 uM measured by crystal violet staining based microplate reader assay	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Discovery of non-proteinogenic amino acids inhibiting biofilm formation by S. aureus and methicillin-resistant S. aureus.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (33.33)	18.7374
1990's	2 (33.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (16.67)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
catechol [no description available]	2.31	1	catechols	allelochemical; genotoxin; plant metabolite
glycine [no description available]	8.09	5	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	2.31	1	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
D-proline [no description available]	2.31	1	D-alpha-amino acid zwitterion; D-alpha-amino acid; proline	mouse metabolite
3-methoxytyrosine 3-O-methyldopa : A L-tyrosine derivative that is the 3-methoxy derivative of L-dopa.	2.31	1	aromatic L-alpha-amino acid zwitterion; L-tyrosine derivative; monomethoxybenzene; non-proteinogenic L-alpha-amino acid	human metabolite
3,5-dibromotyrosine 3,5-dibromotyrosine: used to synthesize various secondary metabolites from marine sponges	2.31	1	monocarboxylic acid
myristic acid Myristic Acid: A saturated 14-carbon fatty acid occurring in most animal and vegetable fats, particularly butterfat and coconut, palm, and nutmeg oils. It is used to synthesize flavor and as an ingredient in soaps and cosmetics. (From Dorland, 28th ed). tetradecanoic acid : A straight-chain, fourteen-carbon, long-chain saturated fatty acid mostly found in milk fat.. tetradecanoate : A long-chain fatty acid anion that is the conjugate base of myristic acid; major species at pH 7.3.	2.37	2	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite
D-serine [no description available]	2.31	1	D-alpha-amino acid; serine zwitterion; serine	Escherichia coli metabolite; human metabolite; NMDA receptor agonist
D-tyrosine [no description available]	2.31	1	D-alpha-amino acid zwitterion; D-alpha-amino acid; tyrosine	Escherichia coli metabolite
phenylalanine [no description available]	2.31	1	D-alpha-amino acid zwitterion; D-alpha-amino acid; phenylalanine
beta-hydroxyphenylalanine beta-hydroxyphenylalanine: RN given refers to beta cpd	2.31	1
dehydroabietic acid dehydroabietic acid: major aquatic toxicant in effluent of pulp and paper mills. dehydroabietic acid : An abietane diterpenoid that is abieta-8,11,13-triene substituted at position 18 by a carboxy group.. dehydroabietate : A monocarboxylic acid anion that is the conjugate base of dehydroabietic acid, obtained by deprotonation of the carboxy group.	2.31	1	abietane diterpenoid; carbotricyclic compound; monocarboxylic acid	allergen; metabolite
3,4-dihydroxybenzyl alcohol 3,4-dihydroxybenzyl alcohol: structure given in first source	2.31	1
quercetin [no description available]	2.31	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger

Condition	Relationship Strength	Studies
Adenocarcinoma, Basal Cell [description not available]	1.99	1
Cancer of Colon [description not available]	1.99	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	1.99	1
Colonic Neoplasms Tumors or cancer of the COLON.	1.99	1
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	1.97	1

n-myristoylglycine

Description

Cross-References

Synonyms (35)

Roles (2)

Drug Classes (2)

Bioassays (2)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.72

Study Types